GNMK—(+34%)—is making decent money selling machines for COVID-19 testing; from 1Q20 PR: https://finance.yahoo.com/news/genmark-diagnostics-provides-preliminary-financial-200310197.html • Total revenue expected to be approximately $38.7 million, representing an increase of approximately 80% over the first quarter of 2019 o ePlex revenue expected to be approximately $34.3 million, an increase of approximately 119% compared to the first quarter of 2019 o Average annuity per analyzer of approximately $214,000, up 29% versus the first quarter of 2019 • COVID-19 positively impacted first quarter placements and revenue o Approximately 80% of gross placements included interest in COVID-19 testing o SARS-CoV-2 consumable revenue accounted for approximately 5% of total ePlex revenue • Gross margin expected to be approximately 40%, compared to 27% in the first quarter of 2019